1. Spaceflight-induced contractile and mitochondrial dysfunction in an automated heart-on-a-chip platform.
- Author
-
Mair DB, Tsui JH, Higashi T, Koenig P, Dong Z, Chen JF, Meir JU, Smith AST, Lee PHU, Ahn EH, Countryman S, Sniadecki NJ, and Kim DH
- Subjects
- Humans, Lab-On-A-Chip Devices, Weightlessness adverse effects, Oxidative Stress, Mitochondria metabolism, Mitochondria, Heart metabolism, Space Flight methods, Myocardial Contraction physiology, Myocytes, Cardiac metabolism
- Abstract
With current plans for manned missions to Mars and beyond, the need to better understand, prevent, and counteract the harmful effects of long-duration spaceflight on the body is becoming increasingly important. In this study, an automated heart-on-a-chip platform was flown to the International Space Station on a 1-mo mission during which contractile cardiac function was monitored in real-time. Upon return to Earth, engineered human heart tissues (EHTs) were further analyzed with ultrastructural imaging and RNA sequencing to investigate the impact of prolonged microgravity on cardiomyocyte function and health. Spaceflight EHTs exhibited significantly reduced twitch forces, increased incidences of arrhythmias, and increased signs of sarcomere disruption and mitochondrial damage. Transcriptomic analyses showed an up-regulation of genes and pathways associated with metabolic disorders, heart failure, oxidative stress, and inflammation, while genes related to contractility and calcium signaling showed significant down-regulation. Finally, in silico modeling revealed a potential link between oxidative stress and mitochondrial dysfunction that corresponded with RNA sequencing results. This represents an in vitro model to faithfully reproduce the adverse effects of spaceflight on three-dimensional (3D)-engineered heart tissue., Competing Interests: Competing interests statement:D.-H.K. is a co-founder, scientific advisory board member, and equity holder of Curi Bio, Inc. N.J.S. is a co-founder with equity of Stasys Medical Corporation and is a scientific advisory board member and equity holder of Curi Bio, Inc. J.H.T. is an employee and equity holder of Tenaya Therapeutics, Inc. The other authors declare no competing interest.
- Published
- 2024
- Full Text
- View/download PDF